Abvc Biopharma (ABVC) Change in Receivables (2012 - 2023)
Abvc Biopharma's (ABVC) quarterly Change in Receivables came in at -$37292.0 in Q4 2023, down 106.4% YoY from $582257.0 in Q4 2022, and down 284.45% on a QoQ basis from -$9700.0 in Q3 2023.
Abvc Biopharma (ABVC) Change in Receivables (2012 - 2023) Analysis & Trends
Abvc Biopharma (ABVC) has 8 years of Change in Receivables data on file, last reported at -$37292.0 in Q4 2023.
- Quarterly Change in Receivables fell 106.4% year-over-year to -$37292.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$228557.0 (down 137.21% YoY) and the FY2023 annual result came in at -$228557.0, down 137.21% from the prior year.
- Change in Receivables slipped to -$37292.0 in Q4 2023, from -$9700.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $582257.0 in Q4 2022 to a low of -$131327.0 in Q2 2019.
- A 5-year average of $26525.5 and a median of -$4233.5 in 2019 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2019 — Change in Receivables soared 1961.93% — and 2023, when it sank 22543.37%.
- Tracing ABVC's Change in Receivables over 5 years: stood at $51582.0 in 2019, then sank by 79.93% to $10355.0 in 2020, then tumbled by 589.38% to -$50675.0 in 2021, then surged by 1249.0% to $582257.0 in 2022, then tumbled by 106.4% to -$37292.0 in 2023.
- The last three Change in Receivables figures came in at -$37292.0 (Q4 2023), -$9700.0 (Q3 2023), and -$68226.0 (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -37,292.00 |
| Dec 31, 2023 | -37,292.00 |
| Sep 30, 2023 | -9,700.00 |
| Sep 30, 2023 | -9,700.00 |
| Jun 30, 2023 | -68,226.00 |
| Jun 30, 2023 | -68,226.00 |
| Mar 31, 2023 | -113,339.00 |
| Mar 31, 2023 | -113,339.00 |
| Dec 31, 2022 | 582,257.00 |
| Dec 31, 2022 | 582,257.00 |
| Sep 30, 2022 | 23,127.00 |
| Sep 30, 2022 | 23,127.00 |
| Jun 30, 2022 | 8,277.00 |
| Jun 30, 2022 | 8,277.00 |
| Mar 31, 2022 | 505.00 |
| Mar 31, 2022 | 505.00 |
| Dec 31, 2021 | -50,675.00 |
| Dec 31, 2021 | -50,675.00 |
| Sep 30, 2021 | 34,343.00 |
| Sep 30, 2021 | 34,343.00 |